AI news
Pathos signs AI neuroscience collaborations with BMS and Tempus
Pathos announced multi-year agreements with Bristol Myers Squibb and Tempus AI for a de-identified neurological dataset and AI-assisted research. Pathos says its five-year Tempus data license is worth $55 million, while BMS receives access to Pathos Foundry and three years of exclusive neuroscience support. The dataset and future treatments are planned outcomes.
Primary source · Pathos AI · October 23, 2026
Opens Pathos AI in a new tab. Read it there before you rely on the summary above.
Read the original
Free, email only
Unlock the full brief free.
- What to check before you trust this story, written down
- Each verified source, with why it matters and who published it
- A note whenever a source has been withdrawn
- Thirty days of stories to browse, not seven
Continuing subscribes the email on that account to Work Worth Doing, my newsletter, the same as the form below, and unlocks every free tool in this browser. We only receive your email address. Unsubscribe in one click.